serine has been researched along with Angiogenesis, Pathologic in 24 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiogenesis-associated eye diseases are among the most common cause of blindness in the United States and worldwide." | 4.83 | Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. ( Rahimi, N, 2006) |
| " The most frequent related adverse events in this group were diarrhea, nausea, and hypertension." | 2.79 | An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. ( Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014) |
| " Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes." | 1.37 | Cardiovascular toxicity profiles of vascular-disrupting agents. ( Lenihan, DJ; Subbiah, IM; Tsimberidou, AM, 2011) |
| "The role of PDGF-DD in pathological angiogenesis and the underlying cellular and molecular mechanisms remain largely unexplored." | 1.36 | Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation. ( Arjunan, P; Chavakis, T; Colosi, P; Dong, L; Hou, X; Kumar, A; Langer, HF; Lee, C; Li, X; Li, Y; Maminishkis, A; Min, W; Tang, Z; Wang, L; Wu, Z; Zhang, F; Zhu, LY, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Supradit, K | 1 |
| Boonsri, B | 1 |
| Duangdara, J | 1 |
| Thitiphatphuvanon, T | 1 |
| Suriyonplengsaeng, C | 1 |
| Kangsamaksin, T | 1 |
| Janvilisri, T | 1 |
| Tohtong, R | 1 |
| Yacqub-Usman, K | 1 |
| Grabowska, AM | 1 |
| Bates, DO | 1 |
| Wongprasert, K | 1 |
| Xiu, M | 1 |
| Li, L | 1 |
| Li, Y | 2 |
| Gao, Y | 1 |
| Ma, M | 1 |
| Zhong, Z | 1 |
| Zhu, Y | 1 |
| Gu, Y | 1 |
| Jin, R | 1 |
| Meng, Z | 1 |
| Wang, Y | 1 |
| Yu, FX | 1 |
| Quatrale, AE | 1 |
| Porcelli, L | 1 |
| Gnoni, A | 1 |
| Numico, G | 1 |
| Paradiso, A | 1 |
| Azzariti, A | 1 |
| Murakami, H | 1 |
| Kurata, T | 1 |
| Onozawa, Y | 1 |
| Watanabe, J | 1 |
| Ono, A | 1 |
| Takahashi, T | 1 |
| Yamamoto, N | 1 |
| Fujisaka, Y | 1 |
| Kiyota, H | 1 |
| Hayashi, H | 1 |
| Tanaka, K | 1 |
| Nakagawa, K | 1 |
| Kuroda, S | 1 |
| Bordeleau, F | 1 |
| Califano, JP | 1 |
| Negrón Abril, YL | 1 |
| Mason, BN | 1 |
| LaValley, DJ | 1 |
| Shin, SJ | 1 |
| Weiss, RS | 1 |
| Reinhart-King, CA | 1 |
| Lin, AH | 1 |
| Eliceiri, BP | 1 |
| Levin, EG | 1 |
| Delmonte, A | 1 |
| Sessa, C | 1 |
| Kumar, A | 1 |
| Hou, X | 1 |
| Lee, C | 1 |
| Maminishkis, A | 1 |
| Tang, Z | 1 |
| Zhang, F | 1 |
| Langer, HF | 1 |
| Arjunan, P | 1 |
| Dong, L | 1 |
| Wu, Z | 1 |
| Zhu, LY | 1 |
| Wang, L | 1 |
| Min, W | 1 |
| Colosi, P | 1 |
| Chavakis, T | 1 |
| Li, X | 1 |
| Murakami, Y | 1 |
| Hosoi, F | 1 |
| Izumi, H | 1 |
| Maruyama, Y | 1 |
| Ureshino, H | 1 |
| Watari, K | 1 |
| Kohno, K | 1 |
| Kuwano, M | 1 |
| Ono, M | 1 |
| Peronneau, P | 1 |
| Lassau, N | 1 |
| Leguerney, I | 1 |
| Roche, A | 1 |
| Cosgrove, D | 1 |
| Cai, YC | 1 |
| Zou, Y | 1 |
| Xian, LJ | 1 |
| Subbiah, IM | 1 |
| Lenihan, DJ | 1 |
| Tsimberidou, AM | 1 |
| Spear, MA | 1 |
| LoRusso, P | 1 |
| Mita, A | 1 |
| Mita, M | 1 |
| Ibrahim, MA | 1 |
| Johnson, HW | 1 |
| Jeong, JW | 1 |
| Lewis, GL | 1 |
| Shi, X | 1 |
| Noguchi, RT | 1 |
| Williams, M | 1 |
| Leahy, JW | 1 |
| Nuss, JM | 1 |
| Woolfrey, J | 1 |
| Banica, M | 1 |
| Bentzien, F | 1 |
| Chou, YC | 1 |
| Gibson, A | 1 |
| Heald, N | 1 |
| Lamb, P | 1 |
| Mattheakis, L | 1 |
| Matthews, D | 1 |
| Shipway, A | 1 |
| Wu, X | 1 |
| Zhang, W | 1 |
| Zhou, S | 1 |
| Shankar, G | 1 |
| Doucette, CD | 1 |
| Hilchie, AL | 1 |
| Liwski, R | 1 |
| Hoskin, DW | 1 |
| Ohno, T | 1 |
| Kawano, K | 1 |
| Sasaki, A | 1 |
| Aramaki, M | 1 |
| Tahara, K | 1 |
| Etoh, T | 1 |
| Kitano, S | 1 |
| Surazynski, A | 1 |
| Liu, Y | 1 |
| Miltyk, W | 1 |
| Phang, JM | 1 |
| Rahimi, N | 1 |
| Ho, YK | 1 |
| Bargagna-Mohan, P | 1 |
| Wehenkel, M | 1 |
| Mohan, R | 1 |
| Kim, KB | 1 |
| Kim, TJ | 1 |
| Ravoori, M | 1 |
| Landen, CN | 1 |
| Kamat, AA | 1 |
| Han, LY | 1 |
| Lu, C | 1 |
| Lin, YG | 1 |
| Merritt, WM | 1 |
| Jennings, N | 1 |
| Spannuth, WA | 1 |
| Langley, R | 1 |
| Gershenson, DM | 1 |
| Coleman, RL | 1 |
| Kundra, V | 1 |
| Sood, AK | 1 |
| Sieving, PA | 1 |
| Boskovich, S | 1 |
| Bingham, E | 1 |
| Pawar, H | 1 |
| Dawson, DW | 1 |
| Volpert, OV | 1 |
| Pearce, SF | 1 |
| Schneider, AJ | 1 |
| Silverstein, RL | 1 |
| Henkin, J | 1 |
| Bouck, NP | 1 |
| Oikawa, T | 1 |
| Hasegawa, M | 1 |
| Shimamura, M | 1 |
| Ashino, H | 1 |
| Murota, S | 1 |
| Morita, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.[NCT00968916] | Phase 1 | 15 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for serine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
An update regarding the role of WNK kinases in cancer.
Topics: Alanine; Animals; Bicarbonates; Mammals; Neoplasms; Neovascularization, Pathologic; Proline; Serine; | 2022 |
New vascular disrupting agents in upper gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Diphosphates; Gastrointestinal Neoplasms; Humans; Neova | 2014 |
AVE8062: a new combretastatin derivative vascular disrupting agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, | 2009 |
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; | 2010 |
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
Topics: Angiogenesis Inhibitors; Blood Vessels; Clinical Trials as Topic; Diketopiperazines; Humans; Neoplas | 2011 |
Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.
Topics: Animals; Endothelial Cells; Enzyme Activation; Eye; Eye Diseases; Humans; Models, Biological; Neovas | 2006 |
1 trial available for serine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Topics: Asian People; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female | 2014 |
17 other studies available for serine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Topics: Arginine; Cholangiocarcinoma; Humans; Neovascularization, Pathologic; Protein Isoforms; Protein Seri | 2022 |
Phosphorylation of NF2 at Serine-13 by MAP4K family kinases mediates pathological angiogenesis.
Topics: Humans; Neovascularization, Pathologic; Phosphorylation; Protein Serine-Threonine Kinases; Serine; S | 2023 |
Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors.
Topics: Alternative Splicing; Animals; Arginine; Binding Sites; Biomechanical Phenomena; Blotting, Western; | 2015 |
FAK mediates the inhibition of glioma cell migration by truncated 24 kDa FGF-2.
Topics: Cell Line, Tumor; Cell Movement; Fibroblast Growth Factor 2; Focal Adhesion Kinase 1; Focal Adhesion | 2009 |
Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation.
Topics: Animals; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Glycogen Synthase Kinase | 2010 |
Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Chemokines, CXC; Humans; Immediate-Early Proteins; Intracellu | 2010 |
Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Contrast Media; Female; Image Enhancement; Im | 2010 |
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplas | 2011 |
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Aniline Compounds; Animals; Antineoplastic Ag | 2012 |
Piperine, a dietary phytochemical, inhibits angiogenesis.
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Aorta; Benzodioxoles; Breast Neoplasms; Cell Movement; | 2013 |
Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Liver Neoplasms, Ex | 2002 |
Nitric oxide regulates prolidase activity by serine/threonine phosphorylation.
Topics: Animals; Blotting, Western; Cyclic GMP; Dipeptidases; DNA, Complementary; Dose-Response Relationship | 2005 |
LMP2-specific inhibitors: chemical genetic tools for proteasome biology.
Topics: Adenocarcinoma; Animals; Catalytic Domain; Cell Line, Tumor; Chymotrypsin; Cysteine Endopeptidases; | 2007 |
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cel | 2007 |
Sorsby's fundus dystrophy in a family with a Ser-181-CVS mutation in the TIMP-3 gene: poor outcome after laser photocoagulation.
Topics: Adult; Choroid; Electroretinography; Female; Fluorescein Angiography; Fundus Oculi; Humans; Laser Co | 1996 |
Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.
Topics: Acetylation; Amino Acid Sequence; Amino Acids; Animals; Cell Movement; Endothelial Growth Factors; E | 1999 |
Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor.
Topics: Allantois; Amides; Animals; Antibiotics, Antineoplastic; Carotid Arteries; Cell Division; Cell Movem | 1991 |